High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy

NeuroRehabilitation

Volumn 34, Issue 3, 2014, Pages 515-522

  Intiso, Domenico ^a   Simone, Valentina ^a,b   Di Rienzo, Filomena ^a   Iarossi, Andrea ^a   Pazienza, Luigi ^a   Santamato, Andrea ^c   Maruzzi, Giuseppe ^a   Basciani, Mario ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b Foundation Rehabilitation 'Gli Angeli di PPio' San Giovanni Rotondo   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Botulinum toxin; brain injury; cerebral palsy; efficacy; high dose; spasticity

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ADULT DISEASE; ANALGESIA; ANKLE; ARM WEAKNESS; ARTICLE; BARTHEL INDEX; BRAIN INJURY; CEREBRAL PALSY; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELBOW; FEMALE; FINGER; FRANCHAY ARM TEST; FUNCTIONAL STATUS; GLASGOW OUTCOME SCALE; HEMATOMA; HEMIPARESIS; HUMAN; INJECTION SITE BLEEDING; INJURY SCALE; MALE; MODIFIED ASHWORTH SCALE; MUSCLE STRENGTH; MUSCLE TONE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PASSIVE MOVEMENT; PILOT STUDY; SIDE EFFECT; SPASTIC PARAPLEGIA; SPASTICITY; VISUAL ANALOG SCALE; WRIST;

BOTULINUM TOXIN; BRAIN INJURY; CEREBRAL PALSY; EFFICACY; HIGH DOSE; SPASTICITY;

ADULT; AGED; ANALYSIS OF VARIANCE; ARM; BOTULINUM TOXINS, TYPE A; BRAIN INJURIES; CEREBRAL PALSY; FEMALE; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 84902278516     PISSN: 10538135     EISSN: 18786448     Source Type: Journal    
DOI: 10.3233/NRE-141052     Document Type: Article

References (38)

1. Ada L., Canning, C., & Dwyer, T. (2000). Effect of muscle length on strength and dexterity after stroke. Clin Rehabil 14, 55-61.
2. Ada L., O'Dwyer, N., & O'Neill, E. (2006). Relation between spas-ticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: An observational study. Disabil Reha-bil 28(13-14) 891-897.
3. Baker, R., Jasinski, M., Maciag-Tymecka, I., Michalowska-Mrozek, J., Bonikowski, M., Carr, L., MacLean, J., Lin, J. P., Lynch, B., Theologis, T., Wendorff, J., Eunson, P., & Cosgrove, A. (2002). Botulinum toxin treatment of spasticity in diplegic cerebral palsy: A randomized, double blind, placebo-controlled, dose ranging study. Dev Med Child Neurol, 44, 666-675.
4. Bakheit, A. M., Pittock, S., Moore, A. P., Wurker, M., Otto, S., Erbguth, F., & Coxon, L. (2001). A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol, 8, 559-565.
5. Barnes, M., Schnitzler, A., Medeiros, L., Aguilar, M., Lehnert-Batar, A., & Minnasch, P. (2010). Efficacy and safety of NT 201 for upper limb spasticityofvarious etiologies-arandomized parallel-group study. Acta Neurol Scand, 122(4), 295-302.
6. Benecke, R., Jost, W. H., Kanovsky, P., Ruzicka, E., Comes, G., & Grafe, S. (2005). A new botulinum toxin type A free of complex-ing proteins for treatment of cervical dystonia. Neurology, 64, 1949-1951.
7. Bergfeldt, U., Borg, K., Kullander, K., & Julin, P. (2006). Focal spas-ticity therapy with botulinum toxin: Effects on function, activities of daily living and painin100 adultpatients.J Rehabil Med, 38(3), 166-171.
8. Bohannon, R., & Smith, M. (1987). Interrater reliability ofa modified Ashworth scale of muscle spasticity. Physical Therapy, 67(2), 206.
9. Caty, G. D., Detrembleur, C., Bleyenheuft, C., Deltombe, T., & Leje-une, T. M. (2009). Effect of upper limb botulinum toxin injection on impairment, activity, participation and quality of life among stroke patients. Stroke, 40, 2589-2591.
10. Clemenzi, A., Formisano, R., Matteis, M., Gallinacci, L., Cochi, G., Savina, P., & Cicinelli, P. (2012). Care management of spasticity with botulinum toxin-A in patients with severe acquired brain injury: A 1-year follow-up prospective study. Brain Inj, 26(7-8), 979-983.
11. Dai, A. I. (2006). Botulinum toxin type a in the management of cerebral palsy: Low or high dose? Pediatr Neurol, 35(6), 446.
12. ®. Mov Disord, 23(Suppl), 20-21.
13. Dressler, D. (2009). Routine use of Xeomin in patients previously treated with Botox: Long term results. Eur J Neurol, 16(Suppl 2), 2-5.
14. Esquenazi, A. (2006). Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol, 13(Suppl 4), 27-34.
15. Fock, J., Galea, M. P., Stillman, B. C., Rawicki, B., & Clark, M. (2004). Functional outcome following botulinum toxin A injec-tiontoreduce spastic equinusinadults with traumatic brain injury. Brain Inj, 8(1), 57-63.
16. Goldstein, E. (2006). Safety of high dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol, 21, 189-192.
17. Gormley, M. E., Gaebler-Spira, D., & Delgado, M. R. (2001). Use of botulinum toxin type A in pediatric patients with cerebral palsy: A three-center retrospective chart review. J Child Neurol, 16(2), 113-118.
18. Graham, H. K., Aoki, K. R., Autti-Rämö, I., Boyd, R. N., Delgado, M. R., Gaebler-Spira, D. J., Gormley, M. E., Guyer, B. M., Heinen, F., Holton, A. F., Matthews, D., Molenaers, G., Motta, F., Garcia Ruiz, P. J., & Wissel, J. (2000). Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture, 11(1), 67-79.
19. Heller, A., Wade, D. T., Wood, V. A., Sunderland, A., Hewer, R. L., & Ward, E. (1987). Arm function after stroke: Measurement and recovery over the first three months. J Neurol Neurosurg Psychiatry, 50(6), 714-719.
20. Inoue, K., Fujinaga, Y., Watanabe Ohyama, T., Takeshi, K., Moriishi, K., Nakajima, H., Inoue, K., & Oguma, K. (1996). Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun, 64, 1589-1594.
21. Jennett, B., & Bond, M. (1975). Assessment of outcome after severe brain damage. A practical scale. Lancet, 1, 480-484.
22. Jost, W. H., Blumel, J., & Grafe, S. (2007). Botulinum neurotoxin type A free of complexing proteins (Xeomin) in focal dystonia. Drugs, 67, 669-683.
23. Kanovsky, P., Slawek, J., Denes, Z., Platz, T., Sassin, I., Comes, G., & Grafe, S. (2009). Efficacy and safety of botulinum neurotoxin NT 201 in post-stroke upper limb spasticity. Clin Neuropharmacol, 32, 259-265.
24. Mahoney, R. I., & Barthel, D. W. (1965). Functional evaluation: The Barthel Index. Md State Med J, 14, 61-65.
25. Medical Research Council: Aids to the investigation of the peripheral nervous system. London, Her Majesty's Stationary Office, 1976.
26. Price, D. D., Bush, F. M., Long, S., & Harkins, S. W. (1994). A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales.Pain, 56, 217-226.
27. Roggenkamper, P., Jost, W. H., Bihari, K., Comes, G., & Grafe, S. (2006). Efficacy and safetyofanewbotulinum toxin typeAfree of complexing proteins in the treatment of blepharospasm. J Neural Transm, 113, 303-312.
28. Santamato, A., Panza, F., Ranieri, M., Frisardi, V., Micello, M. F., Filoni, S., Fortunato, F., Intiso, D., Basciani, M., Logroscino, G., & Fiore, P. (2013). Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm, 120(3), 469-476.
29. Simpson, D. M., Blitzer, A., Brashear, A., Comella, C., Dubinsky, R., Hallett, M., Jankovic, J., Karp, B., Ludlow, C. L., Miyasaki, J. M., Naumann, M., & So, Y. (2008). Assessment: Botulinum neuro-toxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 70, 1691-1698.
30. Thomas, A. M., & Simpson, D. M. (2012). Contralateral weakness following botulinum toxin for poststroke spasticity. Muscle Nerve, 46(3), 443-448.
31. Unlu, E., Cevikol, A., Bal, B., Gonen, E., Celik, O., & Kose, G.(2010). Multilevel botulinum toxin type a as a treatment for spasticity in children with cerebral palsy: A retrospective study. Clinics (Sao Paulo), 65(6):613-619.
32. Varghese-Kroll, E., & Elovic, E. P. (2009). Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil, 88(6), 495-499.
33. Verplancke, D., Snape, S., Salisbury, C. F., Jones, P. W., & Ward, A. B. (2005). A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil, 19(2), 117-125.
34. Willis, A. W., Crowner, B., Brunstrom, J., Kissel, A., & Racette, B. (2007). High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol, 49, 818-822.
35. Wissel, J., Ward, A. B., Erztgaard, P., Bensmail, D., Hecht, M. J., Lejeune, T. M., Schnider, P., Altavista, M. C., Cavazza, S., Del-tombe, T., Duarte, E., Geurts, A. C., Gracies, J. M., Haboubi, N. H., Juan, F. J., Kasch, H., Kätterer, C., Kirazli, Y., Manganotti, P., Parman, Y., Paternostro-Sluga, T., Petropoulou, K., Prempeh, R., Rousseaux, M., Slawek, J., & Tieranta, N. (2009). European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med, 41(1), 13-25.
36. Woldag, H., & Hummelsheim H. (2003). Is the reduction of spas-ticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients? Eur Neurol, 50, 165-171.
37. Yablon, S.A., Brin, M. F., Vandenburgh, A.M., Zhou, J., Garabedian-Ruffalo, S. M., Abu-Shakra, S., & Beddingfield, F. C. (2011). Dose response with onabotulinumtoxinA for post-stroke spastic-ity: A pooled data analysis. Mov Disord, 26(2), 209-215.
38. Zorowitz, R. D., Gillard, P. J., & Brainin, M. (2013). Poststroke spas-ticity: Sequelae and burden on stroke survivors and caregivers. Neurology 15, 80(3 Suppl 2), S45-S52.